SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 16 Change in serum high-density lipoprotein cholesterol in individual studies

Study	Serum high-density lipoprotein cholesterol (mg/dL)			P value	P value between groups
	Group	Baseline	Study completion
Kuchay et al[11]	Empagliflozin	42.0 (12.0)	45.0 (12.0)	0.087	0.752
	Control	45.0 (15.0)	47.0 (12.0)	0.097
Ito et al[12]	Ipragliflozin	48.9 (9.3)	54.7 (10.4)	< 0.05	0.82
	Pioglitazone	47.4 (11.6)	52.7 (13.5)	< 0.05
Eriksson et al[14]	Placebo	51.4 (14.9)	-0.4 (5.0)1	-	-
	Omega-3 CA	49.9 (14.1)	+0.4 (3.2)1	-	Non-significant2
	Dapagliflozin	49.9 (9.5)	+0.4 (4.8)1	-	Non-significant2
	O + D	51.4 (10.2)	+1.6 (5.0)1	-	Non-significant2
Ohki et al[15]	Ipragliflozin	42.0 (40.0-50.0)	44.0 (42.0-59.0)	0.01	-
Seko et al[16]	SGLT-2 inhibitor	53.9 (2.5)	55.4 (2.6)	0.043	-
	Sitagliptin	54.8 (3.3)	55.6 (2.3)	0.531
Sumida et al[18]	Luseogliflozin	55.6 (11.7)	57.5 (13.4)	0.062	-

¹Change from baseline.

²Compared to placebo.

CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.